Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1329-1334

  Airo', Paolo ^a   Ceribelli, Angela ^b   Cavazzana, Ilaria ^a   Taraborelli, Mara ^a   Zingarelli, Stefania ^a   Franceschini, Franco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Anti RNA polymerase III antibodies; Anticentromere antibodies; Antitopoisomerase I antibodies; Malignancy; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, ANTINUCLEAR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMORBIDITY; DNA TOPOISOMERASES, TYPE I; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RETROSPECTIVE STUDIES; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 79959952892     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101144     Document Type: Article

References (22)

1. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008;34:1-15. (Pubitemid 351329460)
2. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119:1005-13. (Pubitemid 23334657)
3. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
4. Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen V. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol 2010;37:603-7.
5. Ceribelli A, Cavazzana I, Airo P, Franceschini F. Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 2010;37:1544.
6. Cavazzana I, Ceribelli A, Airo P, Zingarelli S, Tincani A, Franceschini F. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009;8:580-4.
7. Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009;36:1464-9.
8. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010;62:2787-95.
9. Meyer O, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9. (Pubitemid 46106569)
10. Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010;37:125-30.
11. Codullo V, Morozzi G, Bardoni A, Salvini R, Deleonardi G, De Pita O, et al. Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis. Clin Exp Rheumatol 2007;25:373-7. (Pubitemid 47091013)
12. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6. (Pubitemid 32660630)
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003;Suppl 29:S1-S56.
15. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67. (Pubitemid 29487010)
16. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthtritis Res Ther 2003;5:80-93. (Pubitemid 36849754)
17. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010;12:R54.
18. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4.
19. Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010;163:800-6.
20. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100. (Pubitemid 32094911)
21. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006;54:963-73.
22. Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. Arthritis Rheum 1996;39:686-91. (Pubitemid 26119641)